Aelis Farma Past Earnings Performance

Past criteria checks 0/6

Aelis Farma's earnings have been declining at an average annual rate of -32.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9.1% per year.

Key information

-32.6%

Earnings growth rate

-27.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate9.1%
Return on equity-70.7%
Net Margin-65.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Aelis Farma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:69O Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2411-7315
31 Mar 2412-6316
31 Dec 2312-5316
30 Sep 2311-5215
30 Jun 2310-6214
31 Mar 239-10314
31 Dec 228-14314
30 Sep 228-14312
30 Jun 227-14311
31 Mar 229-629
31 Dec 2111117
30 Sep 2110216
30 Jun 219315
31 Mar 215114
31 Dec 201-213
31 Dec 190-310
31 Dec 180-310
31 Dec 170-110

Quality Earnings: 69O is currently unprofitable.

Growing Profit Margin: 69O is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 69O is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.

Accelerating Growth: Unable to compare 69O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 69O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 69O has a negative Return on Equity (-70.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies